Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Tigecycline
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Tigecycline

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 7 min read

A tetracycline derivative that acts as a protein synthesis inhibitor.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (1,431 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A tetracycline derivative that acts as a protein synthesis inhibitor. It is used as an antibacterial agent for the systemic treatment of complicated skin and intra-abdominal infections. It is also used for the treatment of community-acquired pneumonia.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: 9-(tert-Butylglycylamido)minocycline; TBG-MINO; Tygacil; GAR 936; GAR-936; GAR936.

Where it fits in the MeSH classification

Broader topics
Tetracyclines

Research landscape

PubMed indexes 2,378 records tagged with the MeSH heading “Tigecycline” (counts retrieved 2026-10-31). 797 of them (33.5%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 1,118 records.

Reviews account for 262 records (11.0%) and meta-analyses for 41. Randomized controlled trials number 41 (1.7%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 493 records; 2010-2019: 1,118 records; 2020 onward: 797 records0through 19994932000-20091,1182010-20197972020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-2009493
2010-20191,118
2020 onward797
Share of records by publication typeReviews: 11.0 percent; Meta-analyses: 1.7 percent; Randomized controlled trials: 1.7 percentReviews11.0% (262)Meta-analyses1.7% (41)Randomized controlled trials1.7% (41)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 2,378 PubMed records
TypeRecordsShare
Reviews26211.0%
Meta-analyses411.7%
Randomized controlled trials411.7%

Method: PubMed query "Tigecycline"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae
Lv L, Wan M, Wang C, Gao X, Yang Q, Partridge SR, et al.
2020Research article
Design not recorded in structured metadata
239cc by
PMID 32127452 · DOI · PMC7064769
Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin
Jin X, Chen Q, Shen F, Jiang Y, Wu X, Hua X, et al.
2021Research article
Design not recorded in structured metadata
114cc by
PMID 34074225 · DOI · PMC8205050
Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species
Chen C, Cui CY, Yu JJ, He Q, Wu XT, He YZ, et al.
2020Research article
Design not recorded in structured metadata
75cc by
PMID 33287863 · DOI · PMC7722449
Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistant Klebsiella pneumoniae
Tao X, Xia Y, Zhong L
2026Research article
Design not recorded in structured metadata
2cc by
PMID 41504473 · DOI · PMC12889141

Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae [1]

Research article Lv L, Wan M, Wang C, Gao X, Yang Q, Partridge SR, et al. · · 2020 · cited 239 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Transporters belonging to the chromosomally encoded resistance-nodulation-division (RND) superfamily mediate multidrug resistance in Gram-negative bacteria.
Closing excerpt
The current low prevalence in human clinical isolates provides a precious time window to design and implement measures to tackle this.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (401 words)

Transporters belonging to the chromosomally encoded resistance-nodulation-division (RND) superfamily mediate multidrug resistance in Gram-negative bacteria. However, the cotransfer of large gene clusters encoding RND-type pumps from the chromosome to a plasmid appears infrequent, and no plasmid-mediated RND efflux pump gene cluster has yet been found to confer resistance to tigecycline. Here, we identified a novel RND efflux pump gene cluster, designated tmexCD1-toprJ1, on plasmids from five pandrug-resistant Klebsiella pneumoniae isolates of animal origin. TMexCD1-TOprJ1 increased (by 4- to 32-fold) the MICs of tetracyclines (including tigecycline and eravacycline), quinolones, cephalosporins, and aminoglycosides for K.pneumoniae, Escherichia coli, and Salmonella TMexCD1-TOprJ1 is closely related (64.5% to 77.8% amino acid identity) to the MexCD-OprJ efflux pump encoded on the chromosome of Pseudomonas aeruginosa In an IncFIA plasmid, pHNAH8I, the tmexCD1-toprJ1 gene cluster lies adjacent to two genes encoding site-specific integrases, which may have been responsible for its acquisition. Expression of TMexCD1-TOprJ1 in E. coli resulted in increased tigecycline efflux and in K. pneumoniae negated the efficacy of tigecycline in an in vivo infection model. Expression of TMexCD1-TOprJ1 reduced the growth of E. coli and Salmonella but not K. pneumoniaetmexCD1-toprJ1-positive Enterobacteriaceae isolates were rare in humans (0.08%) but more common in chicken fecal (14.3%) and retail meat (3.4%) samples. Plasmid-borne tmexCD1-toprJ1-like gene clusters were identified in sequences in GenBank from Enterobacteriaceae and Pseudomonas strains from multiple continents. The possibility of further global dissemination of the tmexCD1-toprJ1 gene cluster and its analogues in Enterobacteriaceae via plasmids may be an important consideration for public health planning.IMPORTANCE In an era of increasing concerns about antimicrobial resistance, tigecycline is likely to have a critically important role in the treatment of carbapenem-resistant Enterobacteriaceae, the most problematic pathogens in human clinical settings-especially carbapenem-resistant K.pneumoniae Here, we identified a new plasmid-borne RND-type tigecycline resistance determinant, TMexCD1-TOprJ1, which is widespread among K. pneumoniae isolates from food animals. tmexCD1-toprJ1 appears to have originated from the chromosome of a Pseudomonas species and may have been transferred onto plasmids by adjacent site-specific integrases. Although tmexCD1-toprJ1 still appears to be rare in human clinical isolates, considering the transferability of the tmexCD1-toprJ1 gene cluster and the broad substrate spectrum of TMexCD1-TOprJ1, further dissemination of this mobile tigecycline resistance determinant is possible. Therefore, from a "One Health" perspective, measures are urgently needed to monitor and control its further spread. The current low prevalence in human clinical isolates provides a precious time window to design and implement measures to tackle this.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32127452 · DOI · PMC7064769

Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin [2]

Research article Jin X, Chen Q, Shen F, Jiang Y, Wu X, Hua X, et al. · · 2021 · cited 114 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) has recently aroused increasing attention, especially ST11, the predominant CRKP clone in China.
Closing excerpt
The results indicate that the hypervirulent ST11-KL64 clone is a potential threat to antiinfection treatment and is capable of rapid and diverse evolution of resistance during tigecycline and polymyxin treatment.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (249 words)

Hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) has recently aroused increasing attention, especially ST11, the predominant CRKP clone in China. Here, we report a case of hv-CRKP-associated infection and reveal the in-host evolution of its mechanism of resistance to tigecycline and polymyxin under clinical therapy. A total of 11 K. pneumoniae carbapenemase (KPC)-producing CRKP strains were consecutively isolated from a male patient who suffered from continuous and multisite infections. String and antimicrobial susceptibility tests identified seven hypermucoviscous strains and three tigecycline-resistant and four colistin-resistant strains. Galleria mellonella larvae infection model confirmed the hypervirulence. Pulsed-field gel electrophoresis (PFGE) separated three PFGE clusters among all strains, and further Southern blotting detected that blaKPC-2 was located on the same-sized plasmid. Whole-genome sequencing showed that all strains belonged to the hv-CRKP ST11-KL64 clone. Diverse hypervirulence factors and resistance genes were identified. Further sequencing with the Nanopore platform was performed on the CRKP-Urine1 strain, which contained one virulence plasmid (pVi-CRKP-Urine1) and two resistance plasmids (pKPC-CRKP-Urine1 and pqnrS1-CRKP-Urine1). The gene mutations responsible for tigecycline or colistin resistance were then amplified with PCR followed by sequencing, which indicated that mutations of ramR and lon were the potential loci for tigecycline resistance and that the pmrB, phoQ and mgrB genes for colistin resistance. A novel frameshift mutation of lon was identified in the high-level tigecycline-resistant strain (MIC, 128 mg/L). The results indicate that the hypervirulent ST11-KL64 clone is a potential threat to antiinfection treatment and is capable of rapid and diverse evolution of resistance during tigecycline and polymyxin treatment.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34074225 · DOI · PMC8205050

Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species [3]

Research article Chen C, Cui CY, Yu JJ, He Q, Wu XT, He YZ, et al. · · 2020 · cited 75 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundThe recent emergence and dissemination of high-level mobile tigecycline resistance Tet(X) challenge the clinical effectiveness of tigecycline, one of the last-resort therapeutic options for complicated infections caused by multidrug-resistant Gram-negative and Gram-positive pathogens.
Closing excerpt
Further studies are needed to evaluate the clinical impact of these mobile tigecycline resistance genes.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (337 words)

BackgroundThe recent emergence and dissemination of high-level mobile tigecycline resistance Tet(X) challenge the clinical effectiveness of tigecycline, one of the last-resort therapeutic options for complicated infections caused by multidrug-resistant Gram-negative and Gram-positive pathogens. Although tet(X) has been found in various bacterial species, less is known about phylogeographic distribution and phenotypic variance of different genetic variants.MethodsHerein, we conducted a multiregional whole-genome sequencing study of tet(X)-positive Acinetobacter isolates from human, animal, and their surrounding environmental sources in China. The molecular and enzymatic features of tet(X) variants were characterized by clonal expression, microbial degradation, reverse transcription, and gene transfer experiments, while the tet(X) genetic diversity and molecular evolution were explored by comparative genomic and Bayesian evolutionary analyses.ResultsWe identified 193 tet(X)-positive isolates from 3846 samples, with the prevalence ranging from 2.3 to 25.3% in nine provinces in China. The tet(X) was broadly distributed in 12 Acinetobacter species, including six novel species firstly described here. Besides tet(X3) (n = 188) and tet(X4) (n = 5), two tet(X5) variants, tet(X5.2) (n = 36) and tet(X5.3) (n = 4), were also found together with tet(X3) or tet(X4) but without additive effects on tetracyclines. These tet(X)-positive Acinetobacter spp. isolates exhibited 100% resistance rates to tigecycline and tetracycline, as well as high minimum inhibitory concentrations to eravacycline (2-8 μg/mL) and omadacycline (8-16 μg/mL). Genetic analysis revealed that different tet(X) variants shared an analogous ISCR2-mediated transposon structure. The molecular evolutionary analysis indicated that Tet(X) variants likely shared the same common ancestor with the chromosomal monooxygenases that are found in environmental Flavobacteriaceae bacteria, but sequence divergence suggested separation ~ 9900 years ago (7887 BC), presumably associated with the mobilization of tet(X)-like genes through horizontal transfer.ConclusionsFour tet(X) variants were identified in this study, and they were widely distributed in multiple Acinetobacter spp. strains from various ecological niches across China. Our research also highlighted the crucial role of ISCR2 in mobilizing tet(X)-like genes between different Acinetobacter species and explored the evolutionary history of Tet(X)-like monooxygenases. Further studies are needed to evaluate the clinical impact of these mobile tigecycline resistance genes.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33287863 · DOI · PMC7722449

Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistant Klebsiella pneumoniae [4]

Research article Tao X, Xia Y, Zhong L · · 2026 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The presence of tigecycline heteroresistance in carbapenem-resistant Klebsiella pneumoniae (CRKP) can compromise the efficacy of antimicrobial therapy.
Closing excerpt
Additionally, the study contributes to understanding the role of plasmids in the spread of resistance, emphasizing the need for comprehensive genomic surveillance to inform better antimicrobial strategies.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (444 words)

The presence of tigecycline heteroresistance in carbapenem-resistant Klebsiella pneumoniae (CRKP) can compromise the efficacy of antimicrobial therapy. This study aimed to investigate the phenotypic and genomic characteristics of Tgc-HR in CRKP clinical isolates. A total of 52 non-repetitive CRKP isolates, all tigecycline-susceptible, were collected from January 2021 to December 2023. Tigecycline heteroresistance was confirmed by K-B disk diffusion, E-test screening, growth curves, population analysis profiling (colony pattern analysis), and time-kill curve in this study. Protein fingerprinting clustering, WGS analysis, and bioinformatics were used to investigate the phenotypic characteristics and resistance genes, virulence factors, and plasmid profiles of the isolates. The heteroresistant subclones could proliferate at tigecycline levels as high as 16 mg/L, and their resistant phenotype stayed stable even after repeated passages without antibiotic exposure. Analysis of protein fingerprint clustering suggested that the heteroresistant subclones were derived directly from the original strain, not from contamination by an external strain. All isolates were identified as ST-11 through multilocus sequence typing. The genomic analysis showed that the isolates contained numerous resistance genes, especially the tetracycline efflux pump gene tet(A), β-lactamase genes (blaTEM and blaCTX-M), the aminoglycoside-modifying enzyme gene (aadA), and the efflux pump regulators ramR and acrR. These resistance genes were found to co-occur with virulence factors, such as the type 3 fimbriae (mrk-associated loci), based on genomic co-occurrence analysis (which involves assessing the presence of genes in close proximity or co-localization on the genome), suggesting that resistance and virulence together could heighten pathogenicity and make treatment outcomes more challenging in clinical scenarios. The plasmid typing results indicated that the isolates contained a multireplicon plasmid capable of carrying several resistance genes and closely resembling known high-risk resistant plasmids, aiding in the dissemination of resistance. In this study, we systematically investigated the phenotypic and genomic features of tigecycline heteroresistance among clinical CRKP isolates in China and demonstrated its stability and plausibly genetic basis and hinted at treatment implications. The findings are predictions based off of genomic data estimations and have not been confirmed by transcriptomic nor functional research. More work is required to validate these mechanisms.ImportanceThis study provides crucial insights into the phenomenon of tigecycline heteroresistance (Tgc-HR) in carbapenem-resistant Klebsiella pneumoniae. It highlights the stability of heteroresistant subpopulations and their ability to persist without selective antibiotic pressure, complicating treatment outcomes. The research shows that Tgc-HR is linked to multiple resistance and virulence factors, suggesting a co-evolution of resistance and pathogenicity. This finding underscores the importance of monitoring for heteroresistance in clinical settings, as it may lead to undetected therapeutic failures. Additionally, the study contributes to understanding the role of plasmids in the spread of resistance, emphasizing the need for comprehensive genomic surveillance to inform better antimicrobial strategies.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41504473 · DOI · PMC12889141

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature [5]
    Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. · Drug Resist Updat · 2018 · cited 202 times (Europe PMC)
  • Research article Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis [6]
    Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B · Adv Ther · 2020 · cited 100 times (Europe PMC)
  • Research article Biological Functions and Molecular Mechanisms of Antibiotic Tigecycline in the Treatment of Cancers [7]
    Dong Z, Abbas MN, Kausar S, Yang J, Li L, Tan L, et al. · Int J Mol Sci · 2019 · cited 55 times (Europe PMC)
  • Research article Tigecycline-induced coagulopathy: a literature review [8]
    Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A · Int J Clin Pharm · 2019 · cited 46 times (Europe PMC)
  • Research article Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential [9]
    Kounatidis D, Dalamaga M, Grivakou E, Karampela I, Koufopoulos P, Dalopoulos V, et al. · Biomolecules · 2024 · cited 40 times (Europe PMC)
  • Research article A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii [10]
    Karakonstantis S · J Chemother · 2021 · cited 38 times (Europe PMC)

References

  1. Lv L, Wan M, Wang C, Gao X, Yang Q, Partridge SR, et al.. Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae. . 2020. PMID 32127452 · DOI · PMC7064769
  2. Jin X, Chen Q, Shen F, Jiang Y, Wu X, Hua X, et al.. Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin. . 2021. PMID 34074225 · DOI · PMC8205050
  3. Chen C, Cui CY, Yu JJ, He Q, Wu XT, He YZ, et al.. Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species. . 2020. PMID 33287863 · DOI · PMC7722449
  4. Tao X, Xia Y, Zhong L. Phenotypic and genomic characterization of tigecycline heteroresistance in carbapenem-resistant Klebsiella pneumoniae. . 2026. PMID 41504473 · DOI · PMC12889141
  5. Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al.. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat. 2018. PMID 30447411 · DOI
  6. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Adv Ther. 2020. PMID 32006240 · DOI · PMC7223407
  7. Dong Z, Abbas MN, Kausar S, Yang J, Li L, Tan L, et al.. Biological Functions and Molecular Mechanisms of Antibiotic Tigecycline in the Treatment of Cancers. Int J Mol Sci. 2019. PMID 31336613 · DOI · PMC6678986
  8. Cui N, Cai H, Li Z, Lu Y, Wang G, Lu A. Tigecycline-induced coagulopathy: a literature review. Int J Clin Pharm. 2019. PMID 31713108 · DOI
  9. Kounatidis D, Dalamaga M, Grivakou E, Karampela I, Koufopoulos P, Dalopoulos V, et al.. Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential. Biomolecules. 2024. PMID 39062497 · DOI · PMC11275049
  10. Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. J Chemother. 2021. PMID 32677578 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • MinocyclineDrugs and Chemicals
  • AnthracyclinesDrugs and Chemicals
  • DaunorubicinDrugs and Chemicals
  • EpirubicinDrugs and Chemicals
  • IdarubicinDrugs and Chemicals
  • OxytetracyclineDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

2,378
PubMed records on this heading
34%
published since 2020
262
review articles
41
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • MinocyclineDrugs and Chemicals
  • AnthracyclinesDrugs and Chemicals
  • DaunorubicinDrugs and Chemicals
  • EpirubicinDrugs and Chemicals
  • IdarubicinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support